Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR6 | P46095 | 2/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 9/20 | 0.42 |
| ▸ | DGKA | P23743 | 3/20 | 0.41 |
| ▸ | DGKZ | Q13574 | 3/20 | 0.41 |
| ▸ | SCD | O00767 | 2/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31133689 | 1.00 | GPR6 (0.43) | GPR6CHRM4DGKADGKZSCD | |
| SCHEMBL23527014 | 0.91 | DGKA (0.44) | GPR6CHRM4DGKADGKZSCD | |
| SCHEMBL31133702 | 0.91 | DGKA (0.44) | GPR6CHRM4DGKADGKZSCD | |
| SCHEMBL31133671 | 0.91 | DGKA (0.41) | GPR6CHRM4DGKADGKZSCD | |
| SCHEMBL23527041 | 0.91 | DGKA (0.41) | CHRM4DGKADGKZSCDMCHR1 | |
| SCHEMBL31133615 | 0.91 | CHRM4 (0.47) | GPR6CHRM4DGKADGKZSCD | |
| SCHEMBL23527221 | 0.91 | CHRM4 (0.47) | GPR6CHRM4DGKADGKZSCD | |
| SCHEMBL23527156 | 0.91 | DGKA (0.41) | GPR6CHRM4DGKADGKZSCD | |
| SCHEMBL31133600 | 0.91 | DGKA (0.41) | CHRM4DGKADGKZSCDMCHR1 | |
| SCHEMBL23526869 | 0.90 | DGKA (0.43) | GPR6CHRM4DGKADGKZSCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4081523-B1 | SUBSTITUTED BICYCLIC PIPERIDINE DERIVATIVES USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2024-12-25 | — | — | EP | claimed |
| US-11964973-B2 | Substituted bicyclic compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-23 | — | — | US | claimed |
| WO-2021133750-A1 | SUBSTITUTED BICYCLIC PIPERIDINE DERIVATIVES USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-01 | — | — | WO | claimed |
| US-20210188845-A1 | SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY | 2021-06-24 | — | — | US | claimed |
| EP-4081523-B1 | SUBSTITUTED BICYCLIC PIPERIDINE DERIVATIVES USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2024-12-25 | — | — | EP | disclosed |
| US-11964973-B2 | Substituted bicyclic compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-23 | — | — | US | disclosed |
| WO-2021133750-A1 | SUBSTITUTED BICYCLIC PIPERIDINE DERIVATIVES USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-01 | — | — | WO | disclosed |
| US-20210188845-A1 | SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188845-A1 | SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKA, DGKZ, DGKK | GPR6 422/4885CHRM4 1492/4885DGKA 1/4885 |
| US-11964973-B2 | Substituted bicyclic compounds useful as T cell activators | DGKA, DGKZ, DGKK | GPR6 422/4885CHRM4 1492/4885DGKA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.